Modified LGICs with Altered Ligand Binding, Ion Pore Domains
Summary
USPTO published patent application US20260098076A1 for modified ligand-gated ion channels (LGICs) with altered ligand binding domains and ion pore domains. The invention covers exogenous LGIC ligands, methods for modulating ion transport and cell excitability in mammals, and methods for treating channelopathies. The application was filed on February 24, 2025.
What changed
USPTO published patent application US20260098076A1 covering modified ligand-gated ion channels with altered ligand binding domains (LBD) and ion pore domains (IPD). The application claims exogenous LGIC ligands, methods for modulating ion transport across cell membranes, methods for modulating cell excitability in mammals, and methods for treating channelopathies. Inventors include Scott Sternson, Peter Lee, and Christopher Magnus.
Affected parties include pharmaceutical and biotechnology companies developing ion channel-targeted therapeutics, researchers working on ligand-gated ion channel modulation, and companies seeking to license or challenge the patent claims. The broad claim scope covering both modified LGICs and methods of use may affect freedom-to-operate analyses for competing therapeutic programs targeting the same or similar ion channels.
What to do next
- Monitor patent database for related filings
- Review claims for potential licensing or freedom-to-operate implications
- Assess competitive landscape for ion channel modulation technologies
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE
Application US20260098076A1 Kind: A1 Apr 09, 2026
Inventors
Scott Sternson, Peter Lee, Christopher Magnus
Abstract
This document relates to materials and methods for modulating ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy.
CPC Classifications
C07K 14/70571 A61K 48/0008 A61K 48/0058 A61K 48/0066 A61K 48/0091 C07K 2319/03
Filing Date
2025-02-24
Application No.
19061239
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.